A therapeutic trial with IFN-beta (Hu. Interferon beta lyophilized, Sclavo S.p.A., Siena, Italy), administered thrice weekly but once monthly in six courses was performed for immune-modulating purposes in five parenteral drug addicts affected with lymphadenopathy syndrome. Each dose consisted of 12 X 10(6) international units I.V. Preliminary observations evidenced a significant increase of OKT4+ cells after the first course of therapy. No significant differences from the basal values, though, were found after the following courses, while in a control group of untreated LAS patients, a significant decrease of OKT4+ lymphocytes was observed. Partial remission of symptoms and/or reduction in size of the lymphatic masses were also achieved in all treated patients, although so far none of them can be considered as actually cured.

[Transitory increase of OKT4+ lymphocytes in the peripheral blood of patients with lymphadenopathy syndrome treated with beta-interferon] / M. Galli, A. Lazzarin, G. Poli, C. Negri, G. Orlando, P. Crocchiolo, M. Moroni. - In: QUADERNI SCLAVO DI DIAGNOSTICA CLINICA E DI LABORATORIO. - ISSN 0033-4979. - 21:3(1985 Sep), pp. 322-329.

[Transitory increase of OKT4+ lymphocytes in the peripheral blood of patients with lymphadenopathy syndrome treated with beta-interferon]

M. Galli
Primo
;
A. Lazzarin
Secondo
;
M. Moroni
Ultimo
1985

Abstract

A therapeutic trial with IFN-beta (Hu. Interferon beta lyophilized, Sclavo S.p.A., Siena, Italy), administered thrice weekly but once monthly in six courses was performed for immune-modulating purposes in five parenteral drug addicts affected with lymphadenopathy syndrome. Each dose consisted of 12 X 10(6) international units I.V. Preliminary observations evidenced a significant increase of OKT4+ cells after the first course of therapy. No significant differences from the basal values, though, were found after the following courses, while in a control group of untreated LAS patients, a significant decrease of OKT4+ lymphocytes was observed. Partial remission of symptoms and/or reduction in size of the lymphatic masses were also achieved in all treated patients, although so far none of them can be considered as actually cured.
Antibodies, Monoclonal; Lymphatic Diseases; Immunity, Cellular; Humans; Substance-Related Disorders; Interferon Type I; Pilot Projects; T-Lymphocytes
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/189353
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact